Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
Date:3/3/2010

(1) --- Adjusted net income $27-32 ====== GAAP net income per diluted share $0.27-0.41 Adjusted net income per diluted share $0.80-0.95 Shares used in computing GAAP and adjusted net income per diluted share amounts 34

Non-GAAP Financial Measures

To supplement our financial results and financial guidance presented on a GAAP basis, we use the non-GAAP measures adjusted net income/(loss) and adjusted net income/(loss) per diluted share as shown in the tables above.  These measures exclude (1) revenue related to upfront and milestone payments and gains on sales of products, and (2) certain expenses comprised of amortization and impairment of intangible assets, stock-based compensation and interest expense associated with a debt discount and debt issuance costs.  We believe these non-GAAP financial measures are helpful in understanding our past financial performance and our future results are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with our consolidated financial statements prepared in accordance with GAAP. Our managem
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Across the global healthcare landscape, ... in clinical development, market education, and regulatory compliance. As ... Affairs function is expected to increase in prominence and ... According to research by benchmarking firm, Best Practices, ... dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... March 27, 2015 Object recognition technology has ... impaired and elderly. The VelaSense ® ... lead more independent, productive and fulfilling lives. VelaSense ® ... allow users to identify objects from a one million ... create customized object databases for personal use. ...
(Date:3/27/2015)... Ga. , March 27, 2015  Holographic Optical ... in the field of holographic medical imaging, is entering ... its Kickstarter campaign. Launching on April 20 th , ... and Voxbox Pro. The 8-inch and 22-inch displays will ... home for the first time. In addition to the ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... MYL ) today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... mg, 10 mg, 15 mg, and 20 mg. This product ... ® , which is indicated for the treatment of schizophrenia ...
... Young Innovations, Inc. (NASDAQ: YDNT ) today announced sales ... Sales for the first quarter of 2012 were ... the first quarter of 2011. Income from operations increased 5.3% to ... in the first quarter of 2011. Net income increased 5.6% to ...
Cached Medicine Technology:Mylan Launches Generic Version of Zyprexa® Tablets 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 3Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 4
(Date:3/28/2015)... NY (PRWEB) March 28, 2015 An ... a problem which could prove critical to organizations that ... testing, a critical aspect of data security, is worsening ... industry data security report, every major category out of ... and penetration testing. “With all the craziness that has ...
(Date:3/28/2015)... March 28, 2015 Delaying rotator cuff ... necessary, according to research presented today at the American ... Day. , “Our study compared results for 170 patients ... an additional glenohumeral joint capsule release procedure to relieve ... MD, PhD, lead author from St. George Hospital in ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:3/28/2015)... Purity Products®, a leading direct to ... of their revolutionary new weight loss product, MuffinStop™. ... placebo-controlled clinical studies to be effective in reducing ... is a combination of two traditionally used botanical ... to create one of the most innovative weight ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In her mid-forties ... prevented her from working, Monica K. arrived at JET ... mending department quiet, defensive and scared. The owners and staff ... Support Services (EPSS) to offer jobs to challenged residents ... patience and a willingness to begin with the end in ...
Breaking Medicine News(10 mins):Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3
... Researchers from the University of Pennsylvania School of Medicine ... determines the development of many cell types, and is ... for the maintenance of stem cells. The findings appear ... inhibitors of Notch may not affect bone marrow stem ...
... 1995, Tapped to Steer the World,s Largest Organization ... WHITE PLAINS, N.Y., April 10 The Leukemia & ... chief executive,officer, with the task of leading the world,s ... strives to find cures and,prolong and enhance the lives ...
... survived exposure, study reports, , , THURSDAY, April 10 (HealthDay ... anthrax vaccine that provides protection against the potentially deadly ... and combining two of anthrax,s lethal toxins, the researchers ... be more effective than vaccines that contain just one ...
... - 7,000 deaths ... significantly reduces pharmacy error risk, - Half of consumers choose their ... ... April 10 One-third of America,s 225,million prescription-takers now report experiencing ...
... N.J., April 10 Hooper Holmes,(Amex: HH ) today ... Executive Officer and that Benjamin A. Currier will continue as,Chairman ... a member of the,Board since May 30, 2007, had been ... basis on February 6, 2008., John W. Remshard, who ...
... state,s elderly, disabled, and ... ... cut hundreds of millions of dollars from Medicaid,programs for the elderly, disabled ... the leaders of Florida,s safety net,hospitals warned today., Besides jeopardizing the ...
Cached Medicine News:Health News:Developing cancer treatments directed at critical developmental pathway 2Health News:The Leukemia & Lymphoma Society Announces Appointment of New President and CEO 2Health News:Researchers Pursuing Nasal Anthrax Vaccine 2Health News:Researchers Pursuing Nasal Anthrax Vaccine 3Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 2Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 3Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 2Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 3Health News:Massive Medicaid Cuts Will Impact All Floridians, Safety Net Hospital Leaders Warn 2Health News:Massive Medicaid Cuts Will Impact All Floridians, Safety Net Hospital Leaders Warn 3
RIA kit for the quantitative determination of autoantibodies to IA-2 in serum...
ELISA kit for the quantitative determination of autoantibodies to IA-2 in serum...
Inquire...
Inquire...
Medicine Products: